SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 10-K/A
Amendment NO. 2
(Mark one)
[X] Annual report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the fiscal year ended March 31, 1997
OR
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from __________ to
________
Commission File No. 0-15360
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Oregon 93-1099680
(State of other jurisdiction of (I.R.S. identification
incorporation or organization) employer no.)
7620 SW Bridgeport Road
Portland, Oregon 97224
(Address of principal executive offices) (Zip code)
(503) 639-7221
(Registrant's telephone number, including areas code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange on which
registered
None None
Securities registered pursuant to Section 12(g) of the Act:
Title of Class
Common Stock, no par value
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes
[X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant
to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrants knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. [ ]
State the aggregate market value of voting stock held by non-
affiliates of the registrant, as of May 31, 1997: $17,660,800
Indicate the number of shares outstanding of each of the
registrant's classes of common stock, as of May 31, 1997: Common Stock,
no par value, 19,540,413 shares.
Documents Incorporated by Reference:
Portions of the registrant's definitive Proxy Statement for the 1997
Annual Shareholders' Meeting are incorporated by reference into
Part III
<PAGE>
PART II
Item 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND
RELATED STOCKHOLDER MATTERS
The Company's Common Stock is traded on the NASDAQ National Market
under the Symbol "BJCT." The following table sets forth the high and
low closing sale prices of the Company's Common Stock on the NASDAQ
National Market.
<TABLE>
<CAPTION>
High Low
_____ _____
<S> <C> <C>
Fiscal year Ended March 31, 1995:
First Quarter $3.00 $2.00
Second Quarter 4.13 3.25
Third Quarter 3.63 2.81
Fourth Quarter 2.50 1.50
Fiscal Year Ended March 31, 1996:
First Quarter 3.00 1.44
Second Quarter 2.97 1.19
Third Quarter 2.81 1.81
Fourth Quarter 1.94 1.25
Fiscal Year Ended March 31, 1997:
First Quarter 1.41 1.28
Second Quarter 1.03 0.97
Third Quarter 0.78 0.75
Fourth Quarter 0.78 0.63
The closing sale price on May 30, 1997, as reported on the NASDAQ
National Market, was $0.91 per share. The Company has declared no
dividends during its history and has no intention of declaring a
dividend in the foreseeable future. As of May 30, 1997 the number of
shareholders of record of the Company's Common Stock was 1,423.
<PAGE>
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, Bioject Medical Technologies
Inc. has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized:
BIOJECT MEDICAL TECHNOLOGIES INC.
(Registrant)
By: /S/ PEGGY J. MILLER
Peggy J. Miller
Vice President, Chief Financial
Officer, Secretary/Treasurer
</TABLE>
